Sign in Subscribe
Diseases

Alzheimer's Disease Pipeline Appears Robust With 200+ Key Pharma Companies Actively Working in the Therapeutics Segment

Strategic Insights

— 2 min read

The Alzheimer's disease pipeline is rapidly evolving, with 200+ key pharma companies actively working on therapeutic candidates for the treatment of Alzheimer's disease. A recent report by DelveInsight highlights the comprehensive pipeline landscape, including 220+ pipeline drugs in various stages of development. The pipeline report provides insights into the therapeutic assessment of pipeline drugs by product type, stage, route of administration, and molecule type, offering a deeper understanding of the complex therapeutic landscape.

Key Takeaways:

  • A total of 200+ companies are actively working on 220+ pipeline therapies for Alzheimer's disease treatment, making it a robust pipeline landscape.
  • The pipeline drugs are categorized by their stage of development, with 54% of the pipeline drugs in the early stages (Discovery, Pre-clinical, and Phase I).
  • The top 3 companies with the highest number of pipeline drugs are Anavex Life Sciences Corp. (10), Eli Lilly and Company (9), and Novo Nordisk A/S (9).
  • The most common therapeutic types are Central Nervous System (CNS) drugs (53%), followed by Immunomodulants (17%), and Monoclonal Antibodies (11%).
  • The leading pharma companies involved in Alzheimer's disease pipeline are Anavex Life Sciences Corp., TauRx Therapeutics Ltd, BioVie Inc., AriBio Co., Ltd., Novo Nordisk A/S, AgeneBio, Neurim Pharmaceuticals, and others.
  • Promising pipeline therapies such as SAR110894, Donepezil, Aricept, INM-176, Wujia Yizhi granules, CPC-201, ENA713, memantine ER, Gantenerumab, Solanezumab, Florbetapir F18, and ITI-1284 are under evaluation.
  • DelveInsight's comprehensive report on the Alzheimer's disease pipeline provides valuable insights for companies, investors, and researchers to understand the complex therapeutic landscape and make informed decisions.
  • A summary of clinical trials and emerging therapies for Alzheimer's disease is provided, highlighting the potential treatment options and key players in the field.
  • DelveInsight's in-depth pipeline report on Alzheimer's disease provides the necessary information for understanding the pharma companies, key products, and unmet needs in the field.

Statistics:

  • 200+ key pharma companies are actively working on 220+ pipeline therapies for Alzheimer's disease treatment.
  • The most common therapeutic types in the pipeline are CNS drugs (53%), Immunomodulants (17%), and Monoclonal Antibodies (11%).
  • The top 3 companies with the highest number of pipeline drugs are Anavex Life Sciences Corp. (10), Eli Lilly and Company (9), and Novo Nordisk A/S (9).
  • The pipeline drugs are categorized by their stage of development, with 54% of the pipeline drugs in the early stages (Discovery, Pre-clinical, and Phase I).
  • A total of 250 clinical trials are listed in the pipeline report, highlighting the diverse range of therapies under investigation.
  • The Alzheimer's disease pipeline report provides a comprehensive overview of the pipeline landscape, giving stakeholders a deeper understanding of the therapeutic options available.

Sources:

  • DelveInsight's report, "Alzheimer's Disease Pipeline Insight 2025"
  • M2 COMMUNICATIONS RDATE:10062025 ("M2Presswire-June 11, 2025-")
  • DelveInsight's report, "Alzheimer's Disease Pipeline Insight 2025"
  • M2 COMMUNICATIONS RDATE:10062025 ("M2Presswire-June 11, 2025-")

Read more